Dumon JC - Search Results

1

Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells.

Dumon JC, Journé F, Kheddoumi N, Lagneaux L, Body JJ. Dumon JC, et al. Eur Urol. 2004 Apr;45(4):521-8; discussion 528-9. doi: 10.1016/j.eururo.2003.12.012. Eur Urol. 2004. PMID: 15041119

2

Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study.

Mancini I, Dumon JC, Body JJ. Mancini I, et al. Among authors: dumon jc. J Clin Oncol. 2004 Sep 1;22(17):3587-92. doi: 10.1200/JCO.2004.07.054. J Clin Oncol. 2004. PMID: 15337809

3

Response to alendronate in osteoporotic women previously treated with pamidronate.

Peretz A, Siderova V, Body JJ, Dumon JC, Rozenberg S, Fellemans C, Fuss M, Bergmann P; Interdisciplinary Group for the Study of Bone Diseases and Calcium metabolism (GIPOB). Peretz A, et al. Among authors: dumon jc. Maturitas. 2003 Feb 25;44(2):111-5. doi: 10.1016/s0378-5122(02)00318-3. Maturitas. 2003. PMID: 12590006 Clinical Trial.

4

Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells.

Journe F, Chaboteaux C, Dumon JC, Leclercq G, Laurent G, Body JJ. Journe F, et al. Among authors: dumon jc. Br J Cancer. 2004 Nov 1;91(9):1703-10. doi: 10.1038/sj.bjc.6602181. Br J Cancer. 2004. PMID: 15477866 Free PMC article.

5

Extracellular calcium downregulates estrogen receptor alpha and increases its transcriptional activity through calcium-sensing receptor in breast cancer cells.

Journé F, Dumon JC, Kheddoumi N, Fox J, Laïos I, Leclercq G, Body JJ. Journé F, et al. Among authors: dumon jc. Bone. 2004 Aug;35(2):479-88. doi: 10.1016/j.bone.2004.03.021. Bone. 2004. PMID: 15268900

6

Hypercalcaemia of melanoma: incidence, pathogenesis and therapy with bisphosphonates.

des Grottes JM, Dumon JC, Body JJ. des Grottes JM, et al. Among authors: dumon jc. Melanoma Res. 2001 Oct;11(5):477-82. doi: 10.1097/00008390-200110000-00006. Melanoma Res. 2001. PMID: 11595884

7

Gene therapy clinical trials in Belgium.

Sneyers M, Dumon JC, van Vaerenbergh B, Moens W. Sneyers M, et al. Among authors: dumon jc. Hum Gene Ther. 2001 Jul 1;12(10):1361-5. doi: 10.1089/104303401750271011. Hum Gene Ther. 2001. PMID: 11440629 No abstract available.

8

A novel MVMp-based vector system specifically designed to reduce the risk of replication-competent virus generation by homologous recombination.

Dupont F, Karim A, Dumon JC, Mine N, Avalosse B. Dupont F, et al. Among authors: dumon jc. Gene Ther. 2001 Jun;8(12):921-9. doi: 10.1038/sj.gt.3301477. Gene Ther. 2001. PMID: 11426332

9

Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia.

Body JJ, Louviaux I, Dumon JC. Body JJ, et al. Among authors: dumon jc. Support Care Cancer. 2000 Sep;8(5):398-404. doi: 10.1007/s005200050008. Support Care Cancer. 2000. PMID: 10975689 Clinical Trial.

10

Technical and clinical validation of an immunoradiometric assay for circulating parathyroid hormone-related protein.

Dumon JC, Jensen T, Lueddecke B, Spring J, Barlé J, Body JJ. Dumon JC, et al. Clin Chem. 2000 Mar;46(3):416-8. Clin Chem. 2000. PMID: 10702531 Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25 results

Search Page

Filters